Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript Summary
Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript Summary
Operating expenses in Q3 2024 were $147.1 million, an increase primarily due to personnel-related expenses and a one-time non-cash impairment charge.The following is a summary of the Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript:
以下是inari medical, Inc. (NARI) 2024年第三季度业绩会交易摘要：
Financial Performance:
金融业绩：
Inari Medical reported a Q3 2024 revenue of $153.4 million, which is a 21% year-over-year growth.
Gross margin for Q3 2024 was 87.1%, slightly down from the prior year due to product mix and ramp-up costs associated with new products.
Operating expenses in Q3 2024 were $147.1 million, an increase primarily due to personnel-related expenses and a one-time non-cash impairment charge.
Despite a GAAP operating loss of $13.6 million, the non-GAAP operating loss was $0.4 million, showing significant improvement and movement towards profitability.
inari medical报告2024年第三季度营业收入15340万美元，同比增长21%。
2024年第三季度的毛利率为87.1%，略低于去年，主要是由于产品组合和与新产品相关的增长成本。
2024年第三季度的营业费用为14710万美元，主要增加是由于与人员相关的费用和一项一次性非现金减值损失。
尽管有1360万美元的GAAP营业亏损，但非GAAP营业亏损为40万美元，显示出明显的改善和朝着盈利能力的发展。
Business Progress:
业务进展：
Inari Medical continues to focus on driving adoption of its PE and DVT therapies and emerging therapies portfolio.
Significant progress was made in the international business, with strong revenue growth driven by adoption in Europe and advances in regulatory approvals in Brazil, China, and Japan.
Announced the commencement of a limited market release of the next-gen Artix system in acute limb ischemia, expected to serve a $600 million U.S. TAM.
Introduced next-gen stent delivery system for LimFlow, aiming for broad commercialization in 2025, alongside enhanced inpatient and outpatient reimbursements.
inari medical继续专注于推动其市盈率和DVt疗法以及新兴疗法组合的采用。
在国际业务方面取得了重大进展，欧洲市场的强劲营业收入增长是驱动力，巴西、中国和日本在监管批准方面也有所进展。
宣布在急性肢体缺血领域有限市场推出下一代Artix系统，预计将服务于60000万美元的市场。
推出了面向LimFlow的下一代支架输送系统，旨在在2025年实现广泛商业化，同时增加住院和门诊的报销额。
Opportunities:
机会：
Ongoing commercial and market development efforts are expected to drive robust growth in the U.S. and international markets, particularly with the awaiting PEERLESS study data, which could potentially shift front-line treatment standards in VTE care.
Emerging therapies and international expansions signify strong growth potential, especially with regulatory progress in markets like China and Japan.
正在进行的商业和市场开发工作有望推动美国和国际市场的强劲增长，尤其是在等待PEERLESS研究数据的情况下，这些数据有可能改变深静脉血栓（VTE）治疗的一线标准。
新兴疗法和国际拓展标志着强劲增长潜力，特别是在中国和日本等市场的监管进展方面。
Risks:
风险：
Growth from emerging therapies, such as Artix, expected to be gradual as these products undergo phased market introductions and gauging their market acceptance.
The reliance on PEERLESS study outcomes to potentially influence rapid adoption and standard treatment protocols for PE.
来源于新兴疗法（如Artix）的增长预计将是逐渐的，因为这些产品正在经历分阶段的市场推介，并评估其市场接受程度。
依赖PEERLESS研究结果，有可能影响PE的快速采纳和标准治疗方案。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。
